New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:44 EDTMRNS, LGNDMarinus Pharmaceuticals enters into agreement with CyDex Pharmaceuticals
Marinus Pharmaceuticals (MRNS) announced that it has entered into an agreement with CyDex Pharmaceuticals, a wholly owned subsidiary of Ligand Pharmaceutical (LGND), for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.
News For MRNS;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 18, 2014
10:28 EDTLGNDLigand sees 2015 revenue $81M-$83M, consensus $91.87M
Three estimates make up consensus. Guidance issued in analyst day presentation slides.
10:27 EDTLGNDLigand sees 2017 EPS above $4.65, revenue above $146M
Subscribe for More Information
10:27 EDTLGNDLigand sees 2016 EPS above $3.20, revenue above $107M
Subscribe for More Information
10:25 EDTLGNDLigand guides 2015 EPS $2.14-$2.18, consensus $2.42
Subscribe for More Information
November 14, 2014
17:21 EDTLGNDLigand to host analyst day
Analyst Day to be held in New York on November 18 at 10 am. Webcast Link
November 13, 2014
07:40 EDTMRNSMarinus Pharmaceuticals reports Q3 EPS (22c), consensus (45c)
Subscribe for More Information
November 12, 2014
09:16 EDTLGNDLigand reports GlaxoSmithKline EU regulatory submission for Revolade
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use